Virtual Library
Start Your Search
Yolanda Bautista
Author of
-
+
IASLC Pre-Conference School of Thoracic Oncology (ID 1)
- Event: LALCA 2019
- Type: Invited Speaker Session
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 10/17/2019, 09:00 - 15:30, Castillo A 1-2
-
+
PC1.05 - Planning a Career in Lung Cancer - Clinical (ID 5)
09:00 - 15:30 | Author(s): Yolanda Bautista
- Abstract
Objectives:
Radical treatment in oligometastatic disease in NSCLC has Improved outcome in overall survival. We defined oligometastic disease in patients with less than five synchronous metastases and 3 organs and mediastinal lymph node involvement is not counted as a metastatic site. We describe a single center experience of an academic hospital of oncology assessed by computed tomography for diagnosis, and radiotherapy as a radical treatment.
Materials and Methods:
In this retrospective study we evaluate progression free survival using radiotherapy (stereotactic body radiotherapy and three-dimensional conformal radiotherapy) in patients with oligometastatic NSCLC with pathologically confirmed stage IV NSCLC with ?5 synchronous metastases, and there were assessed by CT. All patients received four to six initial cycles of systemic treatment. We reviewed files from 2017 to 2019. During treatment of radiotherapy patients received pemetrexed as maintenance.
Results:
Sixteen patients were included in the analysis. The mean age was 62.5 years (range: 48-78 years). At diagnosis, 31% of patients presented with CNS metastases. Following radiotherapy, 16 (68.75%) patients achieved a stable disease, while 4 (25%) had a partial response and 1(6.25%) with complete response. The median PFS was 5.7 months (95% CI: 6.3-5.07)
Conclusion:
Patients with oligometastatic NSCLC who undergo radiotherapy have a favorable response and progression free survival.
-
+
Session 12: Presidential Symposium (ID 27)
- Event: LALCA 2019
- Type: Oral Abstract Session
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 10/19/2019, 09:15 - 09:50, Castillo A 1-4
-
+
S2.02 - Long-term Survival Outcomes with Nivolumab (NIVO) in Pts with Previously Treated Advanced Non-small Cell Lung Cancer (NSCLC): Impact of Early Disease Control and Response (ID 106)
09:15 - 09:50 | Author(s): Yolanda Bautista
- Abstract
Background:
Historically, 5-y overall survival (OS) with chemotherapy for pts with metastatic lung cancer was ~5%; with the advent of immunotherapy, this has increased to ~15%. CheckMate (CM) 017, 057, 063, and 003 are NIVO studies with extensive follow-up in pts with previously treated advanced NSCLC. Using pooled data from these studies, we evaluated the long-term benefit (up to 4 y) of NIVO and impact of early response or disease control on subsequent long-term OS.
Method:
Progression-free survival (PFS) and OS were estimated for pts with NSCLC across histologies treated with NIVO in pooled analyses of CM 017, 057, 063, and 003 (n=664), and for pts randomized to NIVO (n=427) or docetaxel (DOC; n=427) in pooled analyses of CM 017/057. Other analyses for CM 017/057 included estimation of OS in pts alive at 6 mo by response status at 6 mo, and OS in all responders (complete or partial response [CR/PR]) from time of response.
Results:
In pooled analyses of the 4 studies, 4-y OS rates for NIVO in all pts and those with PD-L1 ?1% and <1% were 14%, 19%, and 11%, respectively. In CM 017/057, the 4-y OS rate in all pts was higher with NIVO vs DOC (14% vs 5%). Pts with either CR/PR or stable disease (SD) at 6 mo had longer subsequent OS with NIVO vs DOC; for pts with PD at 6 mo, 1-y OS rates were higher with NIVO vs DOC, while 2-4 y OS rates were similar (Table). For responders (CR/PR) in CM 017/057, 4-y OS rate from time of response with NIVO vs DOC was 54% vs 12%; median duration of response was 24 mo vs 6 mo, respectively. Overall, the NIVO discontinuation rate due to treatment-related adverse events (AEs) was 8.7%; most common treatment-related select AEs were skin reactions (incidence rate, 38.6 per 100 person-y).
Conclusion:
These large pooled analyses show pts with CR/PR or SD with NIVO at 6 mo derived marked OS benefit; this long-term benefit was improved vs pts with DOC with the same response status at 6 mo. The NIVO safety profile was consistent with prior reports.
